β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ’ Press Releases
Date | Press release |
---|---|
2025-05-27 07:30:00 | Takeda And Nature Announce Call For Applications Now Open For 2026 Innovators In Science Award Osaka, japan & cambridge, mass.--(business wire)--applications are now open for the takeda innovators in science award with nature recognizing the groundbreaking research of early-career scientists. |
2025-05-14 17:03:00 | The New England Journal Of Medicine Publishes Data From Phase 2b Trial Of Oral Orexin Receptor 2 Agonist Oveporexton (tak-861) In People With Narcolepsy Type 1 Osaka, japan & cambridge, mass.--(business wire)--takeda (tse: 4502/nyse:tak) today announced that the new england journal of medicine published data from the phase 2b trial of oveporexton (tak-861) in people with narcolepsy type 1 (nt1). oveporexton is an investigational oral orexin receptor 2 (ox2r)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes nt1. results demonstrated significant improvement in objective and subjective measure. |
2025-05-08 02:36:00 | Takeda Announces Fy2024 Full Year Results And Fy2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation And Late-stage Pipeline Progress Osaka, japan--(business wire)--takeda (tokyo:4502/nyse:tak) today announced financial results for fiscal year 2024 (period ended march 31, 2025) with continued strong momentum in growth & launch products offsetting loss of exclusivity impact to drive revenue and core operating profit growth, supported by robust cost management. takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. following a positive phase 3 readout for rus. |
2025-05-05 08:00:00 | Biolife Plasma Services Introduces The New Fresenius Kabi Adaptive Nomogram Across Its U.s. Network Of Plasma Donation Centers Bannockburn, ill.--(business wire)--biolife plasma services, part of takeda (tse:4502/nyse:tak), today announced that it has begun introducing the new fresenius kabi adaptive nomogram across its u.s. network of plasma donation centers. the new adaptive nomogram is used on the aurora xi plasmapheresis system, which is in more than half of biolifeβs u.s. plasma donation centers. this new technology will be running in all biolife donation centers using the aurora xi plasmapheresis system by the en. |
2025-04-30 08:05:00 | Takeda Awards $13.8 Million To U.s. Nonprofit Partners To Promote Healthy Eating And Expand Stem Education Cambridge, mass.--(business wire)--takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world. |
2025-04-08 07:15:00 |
|
2025-03-03 06:45:00 |
|
2025-02-24 03:01:00 |
|
2025-01-30 09:00:00 |
|
2025-01-30 02:04:00 |
|
2025-01-30 01:35:00 |
|
2025-01-27 16:05:00 |
|
2024-12-27 01:00:00 |
|
2024-12-03 07:00:00 |
|
2024-11-20 11:30:00 |
|

π° Browse additional press releases for Takeda Pharmaceutical!
Sign up for free or log inπ Discover "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free eBook!